Literature DB >> 21552214

Evaluation of the WHO criteria for the classification of patients with mastocytosis.

Laura Sánchez-Muñoz1, Ivan Alvarez-Twose, Andrés C García-Montero, Cristina Teodosio, María Jara-Acevedo, Carlos E Pedreira, Almudena Matito, Jose Mario T Morgado, Maria Luz Sánchez, Manuela Mollejo, David Gonzalez-de-Olano, Alberto Orfao, Luis Escribano.   

Abstract

Diagnosis and classification of mastocytosis is currently based on the World Health Organization (WHO) criteria. Here, we evaluate the utility of the WHO criteria for the diagnosis and classification of a large series of mastocytosis patients (n=133), and propose a new algorithm that could be routinely applied for refined diagnosis and classification of the disease. Our results confirm the utility of the WHO criteria and provide evidence for the need of additional information for (1) a more precise diagnosis of mastocytosis, (2) specific identification of new forms of the disease, (3) the differential diagnosis between cutaneous mastocytosis vs systemic mastocytosis, and (4) improved distinction between indolent systemic mastocytosis and aggressive systemic mastocytosis. Based on our results, a new algorithm is proposed for a better diagnostic definition and prognostic classification of mastocytosis, as confirmed prospectively in an independent validation series of 117 mastocytosis patients.

Entities:  

Mesh:

Year:  2011        PMID: 21552214     DOI: 10.1038/modpathol.2011.84

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  19 in total

1.  Characterization of Mast Cell Activation Syndrome.

Authors:  Lawrence B Afrin; Sally Self; Jeremiah Menk; John Lazarchick
Journal:  Am J Med Sci       Date:  2016-12-16       Impact factor: 2.378

2.  A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.

Authors:  Jason Gotlib; John H Baird; Tracy I George; Cheryl Langford; Isabel Reyes; Justin Abuel; Cecelia Perkins; Kurt Schroeder; Prithviraj Bose; Srdan Verstovsek
Journal:  Blood Adv       Date:  2019-08-13

3.  Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.

Authors:  Maria Jara-Acevedo; Cristina Teodosio; Laura Sanchez-Muñoz; Ivan Álvarez-Twose; Andrea Mayado; Carolina Caldas; Almudena Matito; José M Morgado; Javier I Muñoz-González; Luis Escribano; Andrés C Garcia-Montero; Alberto Orfao
Journal:  Mod Pathol       Date:  2015-06-12       Impact factor: 7.842

4.  Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis.

Authors:  S Seitz; F Barvencik; T Koehne; M Priemel; P Pogoda; J Semler; H Minne; M Pfeiffer; J Zustin; K Püschel; C Eulenburg; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2013-02-23       Impact factor: 4.507

Review 5.  Hymenoptera Anaphylaxis and C-kit Mutations: An Unexpected Association.

Authors:  Patrizia Bonadonna; Massimiliano Bonifacio; Carla Lombardo; Roberta Zanotti
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

6.  SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes.

Authors:  Katia Hanssens; Fabienne Brenet; Julie Agopian; Sophie Georgin-Lavialle; Gandhi Damaj; Laure Cabaret; Maria Olivia Chandesris; Paulo de Sepulveda; Olivier Hermine; Patrice Dubreuil; Erinn Soucie
Journal:  Haematologica       Date:  2014-01-03       Impact factor: 9.941

Review 7.  Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.

Authors:  John H Baird; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2018-10       Impact factor: 3.952

8.  Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis.

Authors:  I Alvarez-Twose; S Vañó-Galván; L Sánchez-Muñoz; J M Morgado; A Matito; A Torrelo; P Jaén; L B Schwartz; A Orfao; L Escribano
Journal:  Allergy       Date:  2012-03-28       Impact factor: 13.146

9.  Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

Authors:  Eunice Ching Chan; Yun Bai; Arnold S Kirshenbaum; Elizabeth R Fischer; Olga Simakova; Geethani Bandara; Linda M Scott; Laura B Wisch; Daly Cantave; Melody C Carter; John C Lewis; Pierre Noel; Irina Maric; Alasdair M Gilfillan; Dean D Metcalfe; Todd M Wilson
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

Review 10.  Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.

Authors:  Siham Bibi; Melis Dilara Arslanhan; Florent Langenfeld; Sylvie Jeanningros; Sabine Cerny-Reiterer; Emir Hadzijusufovic; Luba Tchertanov; Richard Moriggl; Peter Valent; Michel Arock
Journal:  Haematologica       Date:  2014-03       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.